<DOC>
	<DOCNO>NCT00004174</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat patient stage III stage IV breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation Treating Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose paclitaxel combine high dose cyclophosphamide thiotepa follow autologous peripheral blood stem cell transplantation radiotherapy patient advance breast cancer . II . Assess overall safety toxicity regimen patient . OUTLINE : This dose escalation study paclitaxel . Mobilization harvest : Patients undergo mobilization peripheral blood stem cell ( PBSC ) accord protocol currently use patient may mobilize use cytokine alone chemomobilization discretion attend physician . PBSC harvest select CD34+ cell . If adequate number CD34+ cell harvest , autologous bone marrow may use . Preparative regimen : Patients receive paclitaxel IV 24 hour day -5 high dose thiotepa IV 2 hour high dose cyclophosphamide IV 2 hour day -6 , day -4 follow paclitaxel infusion , day -2 . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 3 6 patient experience dose limit toxicity . Transplantation : PBSC reinfused day 0 minimum 48 hour completion chemotherapy . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 0 continue 3 day blood count recover . Sites pretransplantation metastasis great 3 cm irradiate begin PBSC transplantation blood count recover . Patients follow every month 1 year , every 3 month thereafter . PROJECTED ACCRUAL : Approximately 20 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV breast cancer Must respond disease ( least 50 % reduction sum product diameter measurable nonbony lesion least symptomatic improvement painful bone disease ) follow conventional dose chemotherapy Asymptomatic patient bony disease eligible new lesion evidence bone progression If bone disease present , must new bony lesion follow cytoreductive chemotherapy Patients disease free follow surgery ( e.g. , stage III patient solitary lymph node patient follow excisional biopsy ) eligible No CNS disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Physiologic 60 Menopausal status : Not specify Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin le 2.5 time normal unless due Gilbert 's syndrome SGOT SGPT less 2.5 time normal Alkaline phosphatase less 2.5 time normal If hepatitis C antibody positive , liver function must normal OR liver dysfunction must due metastatic disease chronic hepatitis Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : LVEF least 50 % unless clear cardiologist No myocardial infarction within past 6 month No significant arrhythmia require medication No congestive heart failure Pulmonary : DLCO least 50 % predict FEV1 and/or FVC least 75 % predicted unless due neoplastic pulmonary involvement No serious nonneoplastic pulmonary disease ( severe chronic obstructive lung disease ) would preclude study therapy Other : HIV negative Hepatitis B C surface antigen negative No active serious medical condition would preclude study therapy No allergy Cremophor Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : No 3 prior treatment regimens metastatic disease Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior conventional dose chemotherapy adjuvant treatment advance disease allow Prior doxorubicin great 450 mg/m2 allow dexrazoxane use reduce risk cardiotoxicity At least 3 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy indicator lesion At least 3 week since prior radiotherapy Surgery : See Disease Characteristics At least 3 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>